You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemazepam
Accession NumberDB00231  (APRD00676)
TypeSmall Molecule
GroupsApproved
DescriptionA benzodiazepine that acts as a gamma-aminobutyric acid modulator and anti-anxiety agent. [PubChem]
Structure
Thumb
Synonyms
Restoril
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Co Temazepam Capsules 15mgcapsule15 mgoralCobalt Pharmaceuticals Company2002-08-142015-08-07Canada
Co Temazepam Capsules 30mgcapsule30 mgoralCobalt Pharmaceuticals Company2002-08-142015-08-07Canada
Dom-temazepamcapsule15 mgoralDominion Pharmacal1996-12-16Not applicableCanada
Dom-temazepamcapsule30 mgoralDominion Pharmacal1997-03-16Not applicableCanada
Gen-temazepam 15mgcapsule15 mgoralGenpharm Ulc1997-07-082009-10-15Canada
Gen-temazepam 30mgcapsule30 mgoralGenpharm Ulc1997-07-082009-10-15Canada
Ntp-temazepamcapsule30 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-temazepamcapsule15 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Nu-temazepamcapsule15 mgoralNu Pharm Inc1996-08-162012-09-04Canada
Nu-temazepamcapsule30 mgoralNu Pharm Inc1996-08-162012-09-04Canada
Penta-temazepam Capsulescapsule15 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-temazepam Capsulescapsule30 mgoralPentapharm Ltd.Not applicableNot applicableCanada
PHL-temazepamcapsule15 mgoralPharmel Inc2007-07-27Not applicableCanada
PHL-temazepamcapsule30 mgoralPharmel Inc2007-07-27Not applicableCanada
PMS-temazepamcapsule15 mgoralPharmascience Inc2005-11-29Not applicableCanada
PMS-temazepamcapsule30 mgoralPharmascience Inc2005-11-29Not applicableCanada
PMS-temazepam - 15mgcapsule15 mgoralPharmascience Inc1996-10-172009-10-21Canada
PMS-temazepam - 30mgcapsule30 mgoralPharmascience Inc1996-10-172009-10-21Canada
Ratio-temazepamcapsule15 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-192014-09-19Canada
Ratio-temazepamcapsule30 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-192014-09-19Canada
Restorilcapsule7.5 mg/1oralCardinal Health2008-11-20Not applicableUs
Restorilcapsule30 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs
Restorilcapsule30 mgoralAspri Pharma Canada Inc1980-12-31Not applicableCanada
Restorilcapsule22.5 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs
Restorilcapsule7.5 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs
Restorilcapsule15 mgoralAspri Pharma Canada Inc1980-12-31Not applicableCanada
Restorilcapsule15 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs
Temazepamcapsule7.5 mg/1oralKAISER FOUNDATION HOSPITALS2010-03-23Not applicableUs
Temazepamcapsule7.5 mg/1oralAmerican Health Packaging2012-02-01Not applicableUs
Temazepamcapsule22.5 mg/1oralMallinckrodt, Inc.2010-02-23Not applicableUs
Temazepamcapsule7.5 mg/1oralMallinckrodt, Inc.2010-02-23Not applicableUs
Temazepam-15capsule15 mgoralPro Doc Limitee1997-08-06Not applicableCanada
Temazepam-30capsule30 mgoralPro Doc Limitee1997-08-06Not applicableCanada
Teva-temazepamcapsule15 mgoralTeva Canada Limited1996-12-18Not applicableCanada
Teva-temazepamcapsule30 mgoralTeva Canada Limited1996-12-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-temazepamcapsule15 mgoralApotex Inc1996-10-02Not applicableCanada
Apo-temazepamcapsule30 mgoralApotex Inc1996-10-02Not applicableCanada
Temazepamcapsule7.5 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs
Temazepamcapsule22.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-06-28Not applicableUs
Temazepamcapsule22.5 mg/1oralUnit Dose Services2012-06-28Not applicableUs
Temazepamcapsule15 mg/1oralCardinal Health1988-01-122016-02-25Us
Temazepamcapsule30 mg/1oralProficient Rx LP1986-07-10Not applicableUs
Temazepamcapsule30 mg/1oralAscend Laboratories, LLC1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralKAISER FOUNDATION HOSPITALS2003-06-02Not applicableUs
Temazepamcapsule7.5 mg/1oralMajor Pharmaceuticals2015-03-25Not applicableUs
Temazepamcapsule7.5 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs
Temazepamcapsule15 mg/1oralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs
Temazepamcapsule15 mg/1oralGolden State Medical Supply, Inc.2014-01-10Not applicableUs
Temazepamcapsule15 mg/1oralAphena Pharma Solutions Tennessee, Llc1988-01-12Not applicableUs
Temazepamcapsule15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-12Not applicableUs
Temazepamcapsule30 mg/1oralNovel Laboratories, Inc.2009-10-01Not applicableUs
Temazepamcapsule15 mg/1oralREMEDYREPACK INC.2014-03-19Not applicableUs
Temazepamcapsule15 mg/1oralCardinal Health2012-10-25Not applicableUs
Temazepamcapsule7.5 mg/1oralMc Kesson Packaging Services1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
Temazepamcapsule22.5 mg/1oralMylan Pharmaceuticals Inc.2009-06-15Not applicableUs
Temazepamcapsule15 mg/1oralRx Change Co.2014-11-15Not applicableUs
Temazepamcapsule30 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralDIRECT RX2015-01-01Not applicableUs
Temazepamcapsule30 mg/1oralAphena Pharma Solutions Tennessee, Llc1987-08-03Not applicableUs
Temazepamcapsule15 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs
Temazepamcapsule7.5 mg/1oralNovel Laboratories, Inc.2012-06-22Not applicableUs
Temazepamcapsule15 mg/1oralMylan Institutional Inc.1997-04-29Not applicableUs
Temazepamcapsule30 mg/1oralCardinal Health1988-01-122016-02-25Us
Temazepamcapsule30 mg/1oralProficient Rx LP1987-04-21Not applicableUs
Temazepamcapsule7.5 mg/1oralAscend Laboratories, LLC2012-06-28Not applicableUs
Temazepamcapsule30 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs
Temazepamcapsule15 mg/1oralActavis Elizabeth LLC1995-01-23Not applicableUs
Temazepamcapsule15 mg/1oralSTAT Rx USA LLC1987-08-07Not applicableUs
Temazepamcapsule15 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-08-03Not applicableUs
Temazepamcapsule22.5 mg/1oralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs
Temazepamcapsule30 mg/1oralGolden State Medical Supply, Inc.2014-01-10Not applicableUs
Temazepamcapsule30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-12Not applicableUs
Temazepamcapsule7.5 mg/1oralAv Kare, Inc.2015-08-25Not applicableUs
Temazepamcapsule30 mg/1oralH.J. Harkins Company, Inc.1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralCardinal Health2012-10-25Not applicableUs
Temazepamcapsule30 mg/1oralMc Kesson Packaging Services1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
Temazepamcapsule15 mg/1oralMylan Pharmaceuticals Inc.1986-07-10Not applicableUs
Temazepamcapsule30 mg/1oralLake Erie Medical DBA Quality Care Products LLC1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralUnit Dose Services1987-08-03Not applicableUs
Temazepamcapsule15 mg/1oralPhysicians Total Care, Inc.2008-01-10Not applicableUs
Temazepamcapsule30 mg/1oralDIRECT RX2014-01-01Not applicableUs
Temazepamcapsule30 mg/1oralAphena Pharma Solutions Tennessee, Llc1988-01-12Not applicableUs
Temazepamcapsule15 mg/1oralbryant ranch prepack1987-04-21Not applicableUs
Temazepamcapsule22.5 mg/1oralAscend Laboratories, LLC2012-06-28Not applicableUs
Temazepamcapsule22.5 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs
Temazepamcapsule15 mg/1oralNovel Laboratories, Inc.2009-10-01Not applicableUs
Temazepamcapsule30 mg/1oralMylan Institutional Inc.1997-05-02Not applicableUs
Temazepamcapsule30 mg/1oralCardinal Health2011-02-04Not applicableUs
Temazepamcapsule30 mg/1oralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs
Temazepamcapsule15 mg/1oralDIRECT RX2014-01-01Not applicableUs
Temazepamcapsule15 mg/1oralAphena Pharma Solutions Tennessee, Llc1987-08-03Not applicableUs
Temazepamcapsule30 mg/1oralActavis Elizabeth LLC1995-01-23Not applicableUs
Temazepamcapsule15 mg/1oralRebel Distributors Corp1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Temazepamcapsule15 mg/1oralSandoz Inc1988-01-12Not applicableUs
Temazepamcapsule30 mg/1oralSTAT Rx USA LLC2010-05-24Not applicableUs
Temazepamcapsule15 mg/1oralH.J. Harkins Company, Inc.1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralPd Rx Pharmaceuticals, Inc.1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-09-13Not applicableUs
Temazepamcapsule15 mg/1oralMc Kesson Contract Packaging2011-12-06Not applicableUs
Temazepamcapsule30 mg/1oralMylan Pharmaceuticals Inc.1986-07-10Not applicableUs
Temazepamcapsule15 mg/1oralLake Erie Medical DBA Quality Care Products LLC1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralUnit Dose Services1987-08-03Not applicableUs
Temazepamcapsule30 mg/1oralPhysicians Total Care, Inc.2005-01-11Not applicableUs
Temazepamcapsule15 mg/1oralProficient Rx LP1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralAscend Laboratories, LLC1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralREMEDYREPACK INC.2013-03-26Not applicableUs
Temazepamcapsule15 mg/1oralCardinal Health2011-02-04Not applicableUs
Temazepamcapsule30 mg/1oralbryant ranch prepack1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Temazepamcapsule30 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs
Temazepamcapsule22.5 mg/1oralNovel Laboratories, Inc.2012-06-22Not applicableUs
Temazepamcapsule30 mg/1oralRebel Distributors Corp1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs
Temazepamcapsule15 mg/1oralDIRECT RX2015-01-01Not applicableUs
Temazepamcapsule15 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs
Temazepamcapsule7.5 mg/1oralMylan Pharmaceuticals Inc.2010-05-18Not applicableUs
Temazepamcapsule30 mg/1oralSandoz Inc1988-01-12Not applicableUs
Temazepamcapsule15 mg/1oralSTAT Rx USA LLC2010-05-24Not applicableUs
Temazepamcapsule7.5 mg/1oralMutual Pharmaceutical Company, Inc.2009-09-09Not applicableUs
Temazepamcapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.1987-04-21Not applicableUs
Temazepamcapsule30 mg/1oralTYA Pharmaceuticals1988-01-12Not applicableUs
Temazepamcapsule30 mg/1oralMc Kesson Contract Packaging2011-11-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EuhypnosNot Available
NorkotralNot Available
NormisonNot Available
NortemNot Available
RemestanNot Available
TemazeNot Available
TemtabsNot Available
Brand mixtures
NameLabellerIngredients
StrazepamPhysician Therapeutics Llc
SaltsNot Available
Categories
UNIICHB1QD2QSS
CAS number846-50-4
WeightAverage: 300.74
Monoisotopic: 300.066555377
Chemical FormulaC16H13ClN2O2
InChI KeyInChIKey=SEQDDYPDSLOBDC-UHFFFAOYSA-N
InChI
InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
IUPAC Name
7-chloro-3-hydroxy-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the short-term treatment of insomnia (generally 7-10 days).
PharmacodynamicsTemazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
AbsorptionWell absorbed, minimal first-pass metabolism.
Volume of distributionNot Available
Protein binding96%
Metabolism

Hepatic. Temazepam is completely metabolized through conjugation prior to excretion. The major metabolite is the O-conjugate of temazepam (90%).

SubstrateEnzymesProduct
Temazepam
OxazepamDetails
Temazepam
Not Available
Oxazepam glucuronideDetails
Route of eliminationTemazepam was completely metabolized through conjugation prior to excretion; 80% to 90% of the dose appeared in the urine.
Half life10-20 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9913
Blood Brain Barrier+0.9745
Caco-2 permeable+0.7979
P-glycoprotein substrateNon-substrate0.55
P-glycoprotein inhibitor INon-inhibitor0.7388
P-glycoprotein inhibitor IIInhibitor0.546
Renal organic cation transporterNon-inhibitor0.7776
CYP450 2C9 substrateNon-substrate0.6281
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6962
CYP450 1A2 substrateInhibitor0.5916
CYP450 2C9 inhibitorNon-inhibitor0.5454
CYP450 2D6 inhibitorNon-inhibitor0.891
CYP450 2C19 inhibitorNon-inhibitor0.5615
CYP450 3A4 inhibitorNon-inhibitor0.6014
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6494
Ames testNon AMES toxic0.7974
CarcinogenicityNon-carcinogens0.8093
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.8308
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Tyco healthcare group lp
  • Quantum pharmics ltd
  • Actavis elizabeth llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Novel laboratories inc
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral15 mg
Capsuleoral30 mg
Kit
Capsuleoral15 mg/1
Capsuleoral22.5 mg/1
Capsuleoral30 mg/1
Capsuleoral7.5 mg/1
Prices
Unit descriptionCostUnit
Restoril 22.5 mg capsule11.37USD capsule
Restoril 7.5 mg capsule11.37USD capsule
Temazepam 22.5 mg capsule9.94USD capsule
Temazepam 7.5 mg capsule9.94USD capsule
Restoril 15 mg capsule7.87USD capsule
Restoril 30 mg capsule7.67USD capsule
Temazepam 30 mg capsule0.69USD capsule
Temazepam 15 mg capsule0.58USD capsule
Apo-Temazepam 30 mg Capsule0.14USD capsule
Co Temazepam 30 mg Capsule0.14USD capsule
Novo-Temazepam 30 mg Capsule0.14USD capsule
Pms-Temazepam 30 mg Capsule0.14USD capsule
Ratio-Temazepam 30 mg Capsule0.14USD capsule
Apo-Temazepam 15 mg Capsule0.12USD capsule
Co Temazepam 15 mg Capsule0.12USD capsule
Novo-Temazepam 15 mg Capsule0.12USD capsule
Pms-Temazepam 15 mg Capsule0.12USD capsule
Ratio-Temazepam 15 mg Capsule0.12USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5211954 No1993-05-182010-05-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point119-121 °CPhysProp
water solubility164 mg/LNot Available
logP2.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0534 mg/mLALOGPS
logP2.16ALOGPS
logP2.79ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)10.68ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity81.01 m3·mol-1ChemAxon
Polarizability30.32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-4391000000-eba55d0cdbd09c877424View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
  2. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  3. Vozeh S: [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. [PubMed:6118950 ]
  4. Shats V, Kozacov S: [Falls in the geriatric department: responsibility of the care-giver and the hospital]. Harefuah. 1995 Jun 1;128(11):690-3, 743. [PubMed:7557666 ]
  5. Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [PubMed:18375 ]
External Links
ATC CodesN05CD07
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Temazepam can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Temazepam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Temazepam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Temazepam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Alprazolam.
AminophyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Temazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Temazepam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Temazepam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Temazepam is combined with Amperozide.
AprepitantThe serum concentration of Temazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.
ArmodafinilThe metabolism of Temazepam can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Asenapine.
AtazanavirThe metabolism of Temazepam can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Temazepam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Azaperone.
AzelastineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Temazepam.
BaclofenThe risk or severity of adverse effects can be increased when Temazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Temazepam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Temazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Temazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Temazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Temazepam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Bupivacaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Temazepam is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Butabarbital.
ButacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Temazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Temazepam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Butorphanol.
CapecitabineThe metabolism of Temazepam can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Temazepam is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Temazepam is combined with Carisoprodol.
CelecoxibThe metabolism of Temazepam can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Temazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Temazepam is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Temazepam can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Temazepam can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Temazepam can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Temazepam is combined with Citalopram.
CitalopramThe metabolism of Temazepam can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Temazepam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Temazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Temazepam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonidine.
ClopidogrelThe metabolism of Temazepam can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Temazepam is combined with Clorazepate.
ClotrimazoleThe metabolism of Temazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clozapine.
CobicistatThe metabolism of Temazepam can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Temazepam is combined with Codeine.
ConivaptanThe serum concentration of Temazepam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Temazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Temazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyproheptadine.
DabrafenibThe serum concentration of Temazepam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Temazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dapoxetine.
DarunavirThe metabolism of Temazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Temazepam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Temazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Temazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Temazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Temazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Temazepam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Temazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dihydromorphine.
DiltiazemThe metabolism of Temazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Temazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Temazepam is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Temazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Temazepam is combined with Doxepin.
DoxorubicinThe metabolism of Temazepam can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Temazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Temazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
DronedaroneThe metabolism of Temazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Temazepam is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.
DyphyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Temazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Temazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Temazepam is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Temazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Temazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Temazepam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Temazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Temazepam can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Temazepam can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Eszopiclone.
EthanolTemazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Temazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Temazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Temazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.
EtoperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Etorphine.
EtravirineThe serum concentration of Temazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Temazepam is combined with Felbamate.
FelodipineThe metabolism of Temazepam can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Temazepam is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Temazepam is combined with Flibanserin.
FloxuridineThe metabolism of Temazepam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Temazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flunitrazepam.
FluorouracilThe metabolism of Temazepam can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluoxetine.
FluoxetineThe metabolism of Temazepam can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Temazepam is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Temazepam can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Temazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Temazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Temazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Temazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Temazepam.
FospropofolThe risk or severity of adverse effects can be increased when Temazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Temazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Temazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Temazepam is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Temazepam can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Temazepam is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Temazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Temazepam is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Temazepam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Temazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Iloperidone.
ImatinibThe metabolism of Temazepam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Temazepam is combined with Indalpine.
IndinavirThe metabolism of Temazepam can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Temazepam can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Temazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Isoflurane.
IsoniazidThe metabolism of Temazepam can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Temazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Temazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Temazepam can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Temazepam can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Temazepam is combined with Lamotrigine.
LapatinibThe metabolism of Temazepam can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Temazepam can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Temazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Temazepam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Temazepam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Lofentanil.
LopinavirThe metabolism of Temazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Temazepam.
LosartanThe metabolism of Temazepam can be decreased when combined with Losartan.
LovastatinThe metabolism of Temazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Temazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Temazepam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Temazepam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Temazepam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Temazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Temazepam is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Metaxalone.
MethadoneTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Temazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Temazepam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Temazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Temazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Methylphenobarbital.
MetyrosineTemazepam may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam.
MifepristoneThe metabolism of Temazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Temazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
MirtazapineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Temazepam.
MitotaneThe serum concentration of Temazepam can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Temazepam can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Temazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
NabiloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Nabilone.
NafcillinThe serum concentration of Temazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Temazepam is combined with Nalbuphine.
NefazodoneThe metabolism of Temazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Temazepam can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Temazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Temazepam can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Temazepam can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Temazepam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Temazepam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Temazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.
OlaparibThe metabolism of Temazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Temazepam is combined with Olopatadine.
OmeprazoleThe metabolism of Temazepam can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Temazepam is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Temazepam is combined with Opium.
OrphenadrineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Temazepam.
OsanetantThe risk or severity of adverse effects can be increased when Temazepam is combined with Osanetant.
OsimertinibThe serum concentration of Temazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxymorphone.
PalbociclibThe serum concentration of Temazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Paliperidone.
PantoprazoleThe metabolism of Temazepam can be decreased when combined with Pantoprazole.
ParaldehydeTemazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Temazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.
ParoxetineThe metabolism of Temazepam can be decreased when combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Temazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Temazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Temazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Temazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Temazepam.
PimozideThe risk or severity of adverse effects can be increased when Temazepam is combined with Pimozide.
PioglitazoneThe metabolism of Temazepam can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Temazepam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.
PosaconazoleThe metabolism of Temazepam can be decreased when combined with Posaconazole.
PramipexoleTemazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Temazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Temazepam is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Temazepam is combined with PSD502.
PyrimethamineThe metabolism of Temazepam can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Temazepam can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Quetiapine.
QuinineThe metabolism of Temazepam can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Temazepam can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Temazepam is combined with Ramelteon.
RanolazineThe metabolism of Temazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Temazepam.
RifabutinThe metabolism of Temazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Temazepam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Temazepam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Risperidone.
RitonavirThe metabolism of Temazepam can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Romifidine.
RopiniroleTemazepam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Ropivacaine.
RosiglitazoneThe metabolism of Temazepam can be decreased when combined with Rosiglitazone.
RotigotineTemazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Temazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Temazepam is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Temazepam can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Temazepam is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Temazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Temazepam is combined with Sertraline.
SertralineThe metabolism of Temazepam can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Temazepam is combined with Sevoflurane.
SildenafilThe metabolism of Temazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Temazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Temazepam can be increased when it is combined with Simeprevir.
Sodium oxybateTemazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Temazepam.
SorafenibThe metabolism of Temazepam can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Temazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Temazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.
SulfadiazineThe metabolism of Temazepam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Temazepam can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Temazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Temazepam is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Temazepam is combined with Suvorexant.
TamoxifenThe metabolism of Temazepam can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Temazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Temazepam is combined with Tasimelteon.
TeduglutideThe serum concentration of Temazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Temazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Temazepam can be decreased when combined with Telithromycin.
TeriflunomideThe metabolism of Temazepam can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrodotoxin.
ThalidomideTemazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Temazepam.
TheophyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Thioridazine.
ThiotepaThe metabolism of Temazepam can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiagabine.
TicagrelorThe metabolism of Temazepam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Temazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Temazepam can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Temazepam can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Temazepam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Temazepam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Temazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Temazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Temazepam is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Triflupromazine.
TrimethoprimThe metabolism of Temazepam can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Temazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Temazepam is combined with Valproic Acid.
ValsartanThe metabolism of Temazepam can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Temazepam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Temazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Temazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Vilazodone.
VoriconazoleThe metabolism of Temazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Temazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Yohimbine.
ZafirlukastThe metabolism of Temazepam can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Temazepam is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Temazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Temazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Temazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Temazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Temazepam is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Temazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Temazepam is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Temazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Temazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid avocado.
  • Avoid excessive quantities of coffee or tea (Caffeine).

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. doi: 10.1016/j.pharmthera.2010.01.004. Epub 2010 Feb 4. [PubMed:20138190 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Dobbin M, Martyres RF, Clode D, Champion De Crespigny FE: Association of benzodiazepine injection with the prescription of temazepam capsules. Drug Alcohol Rev. 2003 Jun;22(2):153-7. [PubMed:12850901 ]
  2. Miller EI, Wylie FM, Oliver JS: Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. J Anal Toxicol. 2006 Sep;30(7):441-8. [PubMed:16959136 ]
  3. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D: Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health. 1993 Dec;17(4):345-9. [PubMed:7911332 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. The P450 Program [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, Rushmore TH: Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53. [PubMed:10359672 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23